Ticiana Della-Justina Farias

Dr. Ticiana Della-Justina Farias

University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA
+1
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2021 in Autophagy
Verified
Journal Article
Open access
SCSusanna Croci
Susanna Croci
MVMary Anna Venneri
Mary Anna Venneri
SMStefania Mantovani
Stefania Mantovani
CFChiara Fallerini
Chiara Fallerini
EBElisa Benetti
Elisa Benetti
IMIlaria Meloni
Ilaria Meloni
The polymorphism L412F in TLR3 has been associated with several infectious diseases. However, the mechanism underlying this association is still unexplored. Here, we show that the L412F polymorphism in TLR3 is a marker of severity in COVID-19. This association increases in the sub-cohort of males. Impaired macroautophagy/autophagy and reduced TNF/TNFα production was demonstrated in HEK293 cells transfected with TLR3L412F-encoding plasmid and stimulated with specific agonist poly(I:C). A statistically significant reduced survival at 28 days was shown in L412F COVID-19 patients treated with the autophagy-inhibitor hydroxychloroquine (p = 0.038). An increased frequency of autoimmune disorders such as co-morbidity was found in L412F COVID-19 males with specific class II HLA haplotypes prone to autoantigen presentation. Our analyses indicate that L412F polymorphism makes males at risk of severe COVID-19 and provides a rationale for reinterpreting clinical trials considering autophagy pathways. Abbreviations: AP: autophagosome; AUC: area under the curve; BafA1: bafilomycin A1; COVID-19: coronavirus disease-2019; HCQ: hydroxychloroquine; RAP: rapamycin; ROC: receiver operating characteristic; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; TLR: toll like receptor; TNF/TNF-α: tumor necrosis factor

26 June 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
JFJena D. French
Jena D. French
BHBryan R. Haugen
Bryan R. Haugen
FWFrancis P. Worden
Francis P. Worden
DBDaniel Bowles
Daniel Bowles
AGAndrew G. Gianoukakis
Andrew G. Gianoukakis
LWLori J. Wirth
Lori J. Wirth
Purpose: Lenvatinib, a potent multikinase inhibitor, improves progression-free survival (PFS) in patients with radioiodine (RAI)-refractory differentiated thyroid cancer; however, most patients experience disease progression, warranting further therapy. We evaluated the efficacy and safety of lenvatinib plus pembrolizumab in these patients. Patients and Methods: We enrolled patients with progressive, RAI-refractory differentiated thyroid cancer who were either naïve to multikinase inhibitors (cohort 1) or who had progressed on lenvatinib (cohort 2). Patients received oral lenvatinib daily (cohort 1, 20 mg; cohort 2, dose at progression) and intravenous pembrolizumab (200 mg) every 21 days. Results: In cohorts 1 and 2, 30 and 27 patients were enrolled, respectively. Adverse events were consistent with those observed in other cancers. In cohort 1, the confirmed overall response rate was 65.5%. There were no complete responses (primary endpoint). The 12- and 18-month PFS were 72.0% and 58.0%, respectively, and the median PFS was 26.8 months. In cohort 2, the confirmed overall response rate was 16% (primary endpoint), and the median PFS was 10.0 months (95% confidence interval, 7.0–17.9 months). Tumor histology, driver mutations, and immune-related biomarkers, including PD-L1 expression, thyroid-specific antibody levels, and CD8+ T-cell tumor infiltrate, did not correlate with response to therapy. Increased baseline peripheral blood monocytes and neutrophil to lymphocyte ratio were associated with a worse PFS in cohort 1. Conclusions: Lenvatinib plus pembrolizumab may enhance the durability of lenvatinib monotherapy in lenvatinib-naïve patients. Furthermore, the addition of pembrolizumab may be a viable salvage therapy for patients who have progressed on lenvatinib.

18 October 2023 in HLA
Verified
Journal Article
Open access
TFTiciana Della-Justina Farias
Ticiana Della-Justina Farias
SBSilvia Brugiapaglia
Silvia Brugiapaglia
SCSusanna Croci
Susanna Croci
PMPaola Magistroni
Paola Magistroni
CCClaudia Curcio
Claudia Curcio
AAAntonio Amoroso
Antonio Amoroso
Extreme polymorphism of HLA and killer‐cell immunoglobulin‐like receptors (KIR) differentiates immune responses across individuals. Additional to T cell receptor interactions, subsets of HLA class I act as ligands for inhibitory and activating KIR, allowing natural killer (NK) cells to detect and kill infected cells. We investigated the impact of HLA and KIR polymorphism on the severity of COVID‐19. High resolution HLA class I and II and KIR genotypes were determined from 403 non‐hospitalized and 1575 hospitalized SARS‐CoV‐2 infected patients from Italy collected in 2020. We observed that possession of the activating KIR2DS4*001 allotype is associated with severe disease, requiring hospitalization (OR = 1.48, 95% CI 1.20–1.85, pc = 0.017), and this effect is greater in individuals homozygous for KIR2DS4*001 (OR = 3.74, 95% CI 1.75–9.29, pc = 0.003). We also observed the HLA class II allotype, HLA‐DPB1*13:01 protects SARS‐CoV‐2 infected patients from severe disease (OR = 0.49, 95% CI 0.33–0.74, pc = 0.019). These association analyses were replicated using logistic regression with sex and age as covariates. Autoantibodies against IFN‐α associated with COVID‐19 severity were detected in 26% of 156 hospitalized patients tested. HLA‐C*08:02 was more frequent in patients with IFN‐α autoantibodies than those without, and KIR3DL1*01502 was only present in patients lacking IFN‐α antibodies. These findings suggest that KIR and HLA polymorphism is integral in determining the clinical outcome following SARS‐CoV‐2 infection, by influencing the course both of innate and adaptive immunity.

14 July 2016 in Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms
Verified
Journal Article
Closed access
GCGabriel A. Cipolla
Gabriel A. Cipolla
JPJong Kook Park
Jong Kook Park
LOLiana A. de Oliveira
Liana A. de Oliveira
SLSara Cristina Lobo-Alves
Sara Cristina Lobo-Alves
RARodrigo C. de Almeida
Rodrigo C. de Almeida
MPMaria-Luiza Petzl-Erler
Maria-Luiza Petzl-Erler

6 December 2020 in Immunology
Verified
Journal Article
Closed access
PDF file
STSudan Tao
Sudan Tao
KKKatherine M. Kichula
Katherine M. Kichula
GHGenelle F. Harrison
Genelle F. Harrison
TFTiciana Della-Justina Farias
Ticiana Della-Justina Farias
WPWilliam H. Palmer
William H. Palmer
PNPaul J. Norman
Paul J. Norman

19 May 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
SBSaloe Bispo
Saloe Bispo
TFTiciana Della-Justina Farias
Ticiana Della-Justina Farias
PAPatricia Savio de Araujo-Souza
Patricia Savio de Araujo-Souza
RCRicardo Cintra
Ricardo Cintra
HSHellen Geremias dos Santos
Hellen Geremias dos Santos
FPFabio Passetti
Fabio Passetti
Squamous cell carcinoma (SCC) and adenocarcinoma (ADC) are the most common histological types of cervical cancer (CC). The worse prognosis of ADC cases highlights the need for better molecular characterization regarding differences between these CC types. RNA-Seq analysis of seven SCC and three ADC human papillomavirus 16-positive samples and the comparison with public data from non-tumoral human papillomavirus-negative cervical tissue samples revealed pathways exclusive to each histological type, such as the epithelial maintenance in SCC and the maturity-onset diabetes of the young (MODY) pathway in ADC. The transcriptional regulatory network analysis of cervical SCC samples unveiled a set of six transcription factor (TF) genes with the potential to positively regulate long non-coding RNA genes DSG1-AS1, CALML3-AS1, IGFL2-AS1, and TINCR. Additional analysis revealed a set of MODY TFs regulated in the sequence predicted to be repressed by miR-96-5p or miR-28-3p in ADC. These microRNAs were previously described to target LINC02381, which was predicted to be positively regulated by two MODY TFs upregulated in cervical ADC. Therefore, we hypothesize LINC02381 might act by decreasing the levels of miR-96-5p and miR-28-3p, promoting the MODY activation in cervical ADC. The novel TF networks here described should be explored for the development of more efficient diagnostic tools.